2. Search Result
Search Result
Results for "

plk4+inhibitor

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-12300
    Ocifisertib
    4 Publications Verification

    CFI-400945 free base

    		 Polo-like Kinase (PLK) Apoptosis Cancer
    CFI-400945 free base is a potent, selective and orally bioavailable PLK4 inhibitor with a Ki and an IC50 of 0.26 nM and 2.8 nM, respectively.
    Ocifisertib
  • HY-18683
    Centrinone-B
    Maximum Cited Publications
    8 Publications Verification

    LCR-323

    		 Polo-like Kinase (PLK) Cancer
    Centrinone-B (LCR-323) is a potent and highly selective PLK4 inhibitor, with a Ki of 0.59 nM.
    Centrinone-B
  • HY-172737
    RP-1664

    		Polo-like Kinase (PLK) Cancer
    RP-1664 is a selective and orally active PLK4 inhibitor with an IC50 of 3 nM. RP-1664 demonstrates exquisite selectivity over related kinases, including AURKA/B and PLK1. RP-1664 disrupts centriole biogenesis in cancer cells and leads an accumulation of PLK4 and p21 protein. RP-1664 demonstrates increased sensitivity in TRIM37-high-expressing cells or tumors. RP-1664 exhibits anti-tumor activity in breast cancer and neuroblastoma research [1][2].
    RP-1664
  • HY-12300B
    Ocifisertib fumarate
    4 Publications Verification

    CFI-400945 fumarate

    		 Polo-like Kinase (PLK) Cancer
    CFI-400945 fumarate is a potent, selective and orally bioavailable PLK4 inhibitor with a Ki and an IC50 of 0.26 nM and 2.8 nM, respectively.
    Ocifisertib fumarate
  • HY-134775
    PLK4-IN-1

    		Polo-like Kinase (PLK) Cancer
    PLK4-IN-1 (Example A6) is a PLK4 inhibitor, with an IC50 of ≤ 0.1 μM .
    PLK4-IN-1
  • HY-128493
    PLK4-IN-4

    		Polo-like Kinase (PLK) Cancer
    PLK4-IN-4 (compound 22) is a potent PLK4 inhibitor with an IC50 value of 7.9 nM. PLK4-IN-4 has the potential for the research of cancer .
    PLK4-IN-4
  • HY-115589
    YLT-11

    		Polo-like Kinase (PLK) Apoptosis Cancer
    YLT-11 is a potent, selective and orally active PLK4 inhibitor with Kd values of >10000, 653, >10000, 5.2 nM for PLK1, PLK2, PLK3, PLK4, respectively. YLT-11 shows antiproliferative activity. YLT-11 induces Apoptosis and cell cycle arrest at G2/M phase. YLT-11 show anticancer activity .
    YLT-11
  • HY-176734
    CZL-S092

    		Polo-like Kinase (PLK) Cancer
    CZL-S092 is a PLK4 inhibitor with an IC50 value of 0.9 nM and excellent selectivity over other PLK4 family members (PLK1, PLK2, and PLK3). CZL-S092 exhibits anti-neuroblastoma activity in vitro (IMR-32 cells, IC50 = 1.143 μM). CZL-S092 inhibits cell migration and halts the cell cycle and induces apoptosis. CZL-S092 can be used in studies of various cancers including neuroblastoma cancer .
    CZL-S092
  • HY-179149
    PLK4-IN-6

    		Polo-like Kinase (PLK) Apoptosis Cancer
    PLK4-IN-6 (compound C05) is an PLK4 inhibitor (IC50 < 0.1 nM). PLK4-IN-6 has anti proliferative activity against various tumor cells, such as IMR-32 (IC50 = 0.948 μM), MCF-7 (IC50 = 0.979 μM), H460 (IC50 = 1.679 μM) cells. PLK4-IN-6 can significantly induce cell apoptosis and block the cell cycle. PLK4-IN-6 can be used for research on various types of cancer .
    PLK4-IN-6
  • HY-134775A
    PLK4-IN-3

    		Polo-like Kinase (PLK) Cancer
    PLK4-IN-3 is a less active absolute stereochemistry of PLK4-IN-1. PLK4-IN-1 is a PLK4 inhibitor, with an IC50 of 0.65 μM .
    PLK4-IN-3
  • HY-12300A
    Ocifisertib hydrochloride

    CFI-400945 hydrochloride

    		 Polo-like Kinase (PLK) Apoptosis Cancer
    Ocifisertib hydrochloride (CFI-400945 hydrochloride) is the hydrochloride salt form of Ocifisertib (HY-12300). Ocifisertib hydrochloride is an orally active PLK4 inhibitor with a Ki and an IC50 of 0.26 nM and 2.8 nM. Ocifisertib hydrochloride inhibits growth of various cancer cells, arrests cell cycles at G2/M phase, and induces apoptosis. Ocifisertib hydrochloride exhibits antitumor efficacy in mouse model .
    Ocifisertib hydrochloride
  • HY-162895
    NL13

    		Polo-like Kinase (PLK) Akt CDK Caspase Apoptosis Cancer
    NL13 is a Polo-like kinase 4 (PLK4) inhibitor with an IC50 value of 2.32 μM. NL13 can inhibit the viability of PC3 and DU145 prostate cancer cells, with IC50 values of 3.51 μM and 2.53 μM, respectively. NL13 can lead to the inactivation of the AKT signaling pathway by downregulating CCNB1/CDK1, inducing G2/M cell cycle arrest, and triggering apoptosis through the cleavage of caspase-9/caspase-3. In prostate cancer mice, NL13 can inhibit tumor growth .
    NL13
  • HY-180111
    PLK4-IN-7

    		Polo-like Kinase (PLK) Neurological Disease Cancer
    PLK4-IN-7 is a selective and orally active PLK4 inhibitor with an IC50 value of 7.9 nM. PLK4-IN-7 exhibits potent antitumor activity and favorable metabolic stability. PLK4-IN-7 can be used for the research of tumors such as neuroblastoma .
    PLK4-IN-7

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: